<DOC>
	<DOCNO>NCT02973737</DOCNO>
	<brief_summary>Pyrotinib oral tyrosine kinase inhibitor target HER-1 HER-2 receptor . This study randomize , multi-center , multinational , double blind , active-controlled , parallel design study combination pyrotinib combination capecitabine versus placebo plus capecitabine HER2+ MBC patient , prior receive anthracyclin , taxane trastuzumab . Patients randomize 2:1 ratio one follow treatment arm : Arm A : pyrotinib ( 400 mg daily ) + capecitabine ( 1000 mg/m^2 twice daily ) Arm B : placebo ( 400 mg daily ) + capecitabine ( 1000 mg/m^2 twice daily ) Patients receive either arm therapy occurrence death , disease progression , unacceptable toxicity , specify withdrawal criterion . Patients control group provide pyrotinib treatment progress placebo plus capecitabine treatment .</brief_summary>
	<brief_title>A Study Pyrotinib Plus Capecitabine Patients With HER2+ Metastatic Breast Cancer</brief_title>
	<detailed_description>This study phase 3 , randomize , multi-center , multinational , double blind , active-controlled , parallel design study combination pyrotinib combination capecitabine versus placebo plus capecitabine HER2+ MBC patient , prior receive anthracyclin , taxane trastuzumab . Patients randomize 2:1 ratio one follow treatment arm : Arm A : pyrotinib ( 400 mg daily ) + capecitabine ( 1000 mg/m^2 twice daily ) Arm B : placebo ( 400 mg daily ) + capecitabine ( 1000 mg/m^2 twice daily ) Patients receive either arm therapy occurrence death , disease progression , unacceptable toxicity , specify withdrawal criterion . Efficacy assessment perform screening , every 6 week cycle 18 , every 12 week thereafter . Patients control group provide pyrotinib treatment progress placebo plus capecitabine treatment . Pyrotinb administrate patient reach progress wit</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>1 . Aged ≥18 ≤75 year . 2 . ECOG performance status 0 1 . 3 . Life expectancy 12 week . 4 . According RECIST 1.1 , least one measurable lesion exist 5 . Histologically cytologic confirm HER2 positive advance breast cancer fail prior therapy . 6 . Prior treatment trastuzumab ( ≥2 cycle metastatic setting , ≥3 month adjuvant set ) , patient available trastuzumab lapatinib 7 . Previously reveived Anthracyclin Taxane . 8 . Required laboratory value include follow parameter : ANC : ≥ 1.5 x 10^9/L ; Platelet count : ≥ 90 x 10^9/L ; Hemoglobin : ≥ 9.0 g/dL ; Total bilirubin : ≤ 1.5 x upper limit normal ( ULN ) ; ALT AST : ≤ 2 x ULN ( patient liver metastasis : &lt; /= 5 x ULN ) ; BUN Creatinine : ≤ 1.5 x ULN ; LVEF : ≥ 50 % ; QTcF : &lt; 470 ms. 9 . Signed informed consent 1 . Received previous therapy lapatinib , neratinib , pyrotinib HER2 directe tyrosine kinase inhibitor . 2 . Received previous therapy capecitabine . 3 . History receive chemotherapy , targettherapy investigational treatment within 28 day prior randomization . Received hormone therapy within 7 day prior randomization . 4 . Brain metastasis untreated , symptomatic , require therapy control symptom . 5 . Current severe , uncontrolled systemic disease . 6 . Unable unwilling swallow tablet .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>